SLC5A2 and cardiovascular disorder: Particularly, beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), sodium-glucose cotransporter-2 inhibitors (SGLT2-is), and either angiotensin-converting enzyme inhibitors (ACEis)/angiotensin receptor blockers (ARBs) or angiotensin receptor neprilysin inhibitors (ARNIs) have been shown to be related to an increase in prognosis and a reduction in hospitalization due to cardiovascular diseases [3].